Identification of **SCN1A** and **PCDH19** Mutations in Chinese Children with Dravet Syndrome

Anna Ka-Yee Kwong, Cheuk-Wing Fung, Siu-Yuen Chan, Virginia Chun-Nei Wong*

Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

### Abstract

**Background:** Dravet syndrome is a severe form of epilepsy. Majority of patients have a mutation in **SCN1A** gene, which encodes a voltage-gated sodium channel. A recent study has demonstrated that 16% of **SCN1A**-negative patients have a mutation in **PCDH19**, the gene encoding protocadherin-19. Mutations in other genes account for only a very small proportion of families. **TSPYL4** is a novel candidate gene within the locus 6q16.3-q22.31 identified by linkage study.

**Objective:** The present study examined the mutations in epileptic Chinese children with emphasis on Dravet syndrome.

**Methods:** A hundred children with severe epilepsy were divided into Dravet syndrome and non-Dravet syndrome groups and screened for **SCN1A** mutations by direct sequencing. **SCN1A**-negative Dravet syndrome patients and patients with phenotypes resembling Dravet syndrome were checked for **PCDH19** and **TSPYL4** mutations.

**Results:** Eighteen patients (9 males, 9 females) were diagnosed to have Dravet syndrome. Among them, 83% (15/18) had **SCN1A** mutations including truncating (7), splice site (2) and missense mutations (6). The truncating/splice site mutations were associated with moderate to severe degree of intellectual disability (p<0.05). During the progression of disease, 73% (11/15) had features fitting into the diagnostic criteria of autism spectrum disorder and 53% (8/15) had history of vaccination-induced seizures. A novel **PCDH19** p.D377N mutation was identified in one **SCN1A**-negative female patient with Dravet syndrome and a known **PCDH19** p.N340S mutation in a female non-Dravet syndrome patient. The former also inherited a **TSPYL4** p.G60R variant.

**Conclusion:** A high percentage of **SCN1A** mutations was identified in our Chinese cohort of Dravet syndrome patients but none in the rest of patients. We demonstrated that truncating/splice site mutations were linked to moderate to severe intellectual disability in these patients. A de novo **PCDH19** missense mutation together with an inherited **TSPYL4** missense variant were identified in a patient with Dravet syndrome.

### Citation

Kwong AK-Y, Fung C-W, Chan S-Y, Wong VC-N (2012) Identification of **SCN1A** and **PCDH19** Mutations in Chinese Children with Dravet Syndrome. PLoS ONE 7(7): e41802. doi:10.1371/journal.pone.0041802

### Keywords

EPD; Autism spectrum disorder; Vaccination-induced seizures; Chinese children; Mutations; Dravet syndrome; SCN1A; PCDH19; TSPYL4

### Acknowledgments

The authors have declared that no competing interests exist.

* E-mail: vcnwong@hku.hk

---

**Introduction**

**SCN1A** is regarded as the most important epilepsy gene associated with a spectrum of epilepsy syndromes ranging from milder phenotypes in generalized epilepsy with febrile seizures plus (GEFS+) to severe myoclonic epilepsy of infancy (Dravet syndrome). GEFS+ is inherited in an autosomal-dominant pattern [1]. It includes a spectrum of phenotypes with mild and severe forms of epilepsy associated with febrile and afebrile seizure. The most severe form in GEFS+ spectrum is Dravet syndrome (DS) [2]. DS is defined by febrile and afebrile generalized and unilateral, clonic or tonic-clonic seizures which begin in the first year of life [3]. The seizure begins in form of prolonged febrile seizures which may evolve to status epilepticus [1,4,5]. Other seizure types such as myoclonic, focal, absence and tonic seizures emerge later. Development is normal in the first year but delayed from the second year of life followed by cognitive and personality impairment. Pyramidal signs and ataxia may evolve. The overall syndrome in DS is resistant to antiepileptic drugs.

**SCN1A** is the gene encoding the α1 pore-forming subunit of voltage-gated sodium channel which plays an important role for initiating and propagating action potentials in the central nervous system [6]. This subunit consists of four homologous domains (D1–D4) and each domain contains 6 transmembrane segments (S1–S6) [7]. To date, more than 600 **SCN1A** variants have been identified throughout the whole gene [8]. These mutations may alter the function of the channel leading to abnormal hyperexcitability of neural network and resulting in epileptic seizure [9]. Although **SCN1A** mutations were initially identified in GEFS+ families [7], most of the mutations were found in DS patients. Majority (70–80%) of DS patients were found to have a point mutation or gross rearrangement in their **SCN1A** gene [10,11,12]. The remaining 20–30% of the patients presented with the same severe phenotype of a high rate of epilepsy. Mutations in other genes have been reported in these patients [13].

---

**SCN1A** is regarded as the most important epilepsy gene associated with a spectrum of epilepsy syndromes ranging from milder phenotypes in generalized epilepsy with febrile seizures plus (GEFS+) to severe myoclonic epilepsy of infancy (Dravet syndrome). GEFS+ is inherited in an autosomal-dominant pattern [1]. It includes a spectrum of phenotypes with mild and severe forms of epilepsy associated with febrile and afebrile seizure. The most severe form in GEFS+ spectrum is Dravet syndrome (DS) [2]. DS is defined by febrile and afebrile generalized and unilateral, clonic or tonic-clonic seizures which begin in the first year of life [3]. The seizure begins in form of prolonged febrile seizures which may evolve to status epilepticus [1,4,5]. Other seizure types such as myoclonic, focal, absence and tonic seizures emerge later. Development is normal in the first year but delayed from the second year of life followed by cognitive and personality impairment. Pyramidal signs and ataxia may evolve. The overall syndrome in DS is resistant to antiepileptic drugs.

**SCN1A** is the gene encoding the α1 pore-forming subunit of voltage-gated sodium channel which plays an important role for initiating and propagating action potentials in the central nervous system [6]. This subunit consists of four homologous domains (D1–D4) and each domain contains 6 transmembrane segments (S1–S6) [7]. To date, more than 600 **SCN1A** variants have been identified throughout the whole gene [8]. These mutations may alter the function of the channel leading to abnormal hyperexcitability of neural network and resulting in epileptic seizure [9]. Although **SCN1A** mutations were initially identified in GEFS+ families [7], most of the mutations were found in DS patients. Majority (70–80%) of DS patients were found to have a point mutation or gross rearrangement in their **SCN1A** gene [10,11,12]. The remaining 20–30% of the patients presented with the same severe phenotype of a high rate of epilepsy. Mutations in other genes have been reported in these patients [13].
Mutations in PCDH19 have been reported in patients with epilepsy and mental retardation limited to females (EFMR), which is X-linked and connected through unaffected transmitting males [14,15,16]. PCDH19 encodes protocadherin-19, a protein belonging to the delta-2 protocadherin subclass of the cadherin superfamily. It is a calcium-dependent cell-cell adhesion protein primarily expressed in the nervous system and is involved in neuronal connections and signal transductions at the synaptic membrane [17,18,19,20]. EFMR can be differentiated from DS with clinical features being highly variable with the onset of seizures ranging from 6 to 36 months, combination of febrile and afebrile seizures and variable degree of psychomotor delay and cognitive impairment [21,22]. In a recent study, Depienne et al [22] identified point mutations in PCDH19 genes in a group of SCN1A-negative patients with DS. They found that 16% of SCN1A-negative DS patients were PCDH19-positive and PCDH19 might overall account for 5% of DS patients. Although the clinical features of PCDH19-DS patients were slightly different from the classical SCN1A-DS patients, their results demonstrated that PCDH19 was involved in epileptic encephalopathies clinically overlapping with DS.

Mutations in two other genes encoding sodium channel subunits (SCN1B, SCN2A) and 2 genes encoding GABA receptor subunits (GABRB2 and GABRD) have been found in a few GEFS+ families. The discovery of more susceptibility genes is important for the improvement of genetic diagnosis and management of epilepsy syndromes. In a recent study, computational disease gene prioritization based on expression pattern in Human Brain Gene Expression Atlases was applied to evaluate the candidate genes in previously mapped novel susceptible GEFS+ locus 6q16.3-q22.31 [23,24]. TSPYL1 and TSPYL4 genes, two members of nucleosome assembly protein, were found to be outstanding candidates for GEFS+. As nucleosome assembly protein can regulate gene expression and may present a novel mechanism for disease, we have investigated TSPYL1 and TSPYL4 sequence variations in this study.

In the present study, SCN1A mutation analysis was performed in 100 patients recruited from the Epilepsy Clinic of Queen Mary Hospital and Duchess of Kent Children’s Hospital, being affiliated hospitals of the University of Hong Kong. The cohort was divided into two groups. The first group included 18 patients who developed severe epilepsies and were diagnosed clinically to have DS. The second group consisted of 82 patients with other epileptic phenotypes who did not fit into the diagnostic criteria of DS. We aimed to study the rate of SCN1A mutations in these two groups of patients and further investigate the association between SCN1A mutation and phenotype. In addition, mutations in TSPYL4 and PCDH19 were identified in two patients, with one of them carrying both PCDH19 and TSPYL4 mutations.

Methods

Ethics Statement

This study was approved by the Institutional Review Board of the Hong Kong West Cluster and the University of Hong Kong (IRB Ref. No.: UW 11-190). Written informed consent was obtained from the parents of children involved in the study since 2011. Prior to 2011, documented verbal consent was obtained from the subjects’ parents. All data were analyzed anonymously.

Patient Samples and Clinical Diagnoses

One hundred patients with epilepsy being actively followed up in the Epilepsy Clinic of Queen Mary Hospital and Duchess of Kent Children’s Hospital were recruited. Informed consent was obtained from their parents. Clinical data including the age of onset, seizure types, precipitating factors, developmental course, and family history of seizures, imaging and EEG reports were evaluated retrospectively. Children with autistic features were diagnosed to be autism spectrum disorder (ASD) based on DSM IV TR diagnostic criteria. Patients with intellectual disability (ID) were assessed according to their scores of general/developmental quotients as mild ID (general quotient = 50–70), moderate ID (general quotient = 25–50) or severe ID (general quotient < 25).

The DS patients were identified based on International League Against Epilepsy (ILAE) classification (1981, 1989) and core DS phenotypes defined by Dravet [3] including normal development before onset of seizure, onset in the first year of age by febrile or afebrile clonic and tonic-clonic, generalized and unilateral seizure, often prolonged, subsequent appearance of multiple seizure types including myoclonic, atypical absences and focal seizures and delay in developmental and cognitive skills. DS included both severe myoclonic epilepsy of infancy and borderline severe myoclonic epilepsy of infancy [5]. Both the 18 DS patients and the remaining 82 non-DS patients were screened for SCN1A mutations. Among the non-DS patients, 25 patients (12 male, 13 female) with clinical features resembling DS but varying in two criteria from DS phenotypes such as late seizure onset, less intractable seizure, absence of status epilepticus, myoclonic jerks or atypical absences were selected for PCDH19 and TSPYL4 mutation study.

Control DNA samples were extracted from blood collected from Hong Kong Red Cross. A hundred control alleles were sequenced to confirm the mutations detected in the present study were not polymorphisms.

Molecular Analysis of SCN1A Gene

Polymerase chain reaction. Genomic DNA samples of the 100 patients were extracted from peripheral blood using Flexigene DNA Kit (Qiagen GmbH, Germany). All 26 exons of SCN1A including the splice junctions were amplified by polymerase chain reaction (PCR) using oligonucleotide primers designed based on the sequence of SCN1A gene on human chromosome 2 (GeneBank accession number: NC_000002.11). PCR contained 0.1 μg of genomic DNA as template, 5 pmol of each primer, 200 μM of deoxyribonucleoside triphosphates, and 0.5 U HotStarTaq Plus DNA Polymerase (Qiagen) in 1X Qiagen PCR buffer. PCR was carried out with initial enzyme activation at 95°C for 5 minutes, followed by 50 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 1 minute and extension at 72°C for 1.5 minutes, with a final extension at 72°C for 10 minutes. The quality and quantity of PCR products were checked by electrophoresis.

DNA sequencing. PCR products were sequenced by Bigdye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystem, Foster City, CA) using either the original PCR primers or nested intron flanking primers. Sequences were analyzed on a 3730xl sequencer (Applied Biosystems). Homology analyses with SCN1A reference sequence were performed using NCBI program BLAST®. The numbering for each mutation was taken from the start codon with +1 corresponding to the A of the ATG in the reference sequence of SCN1A isoform 1 (Genbank accession number: NM_001165963). SCN1A mutations or sequence variants were discriminated from single nucleotide polymorphisms (SNP) reported in NCBI SNP and Ensembl SNP database. Novel mutations were verified by checking the already identified SCN1A variants in the SCN1A Variant Database [8]. The parental DNA was collected and sequenced to distinguish between de novo and familial variants.
Pathogenicity assessment of mutation. Several analyses were used to evaluate the pathogenicity of the missense mutation. Firstly, conservative analyses were performed to predict whether the amino acid substitutions in missense mutations affect protein function based on the degree of conservation at the affected residues. Human SCN1A amino acid sequences were aligned with the paralogous and orthologous sequences by an online program ClustalW2 Multiple Sequence Alignment (European Bioinformatics Institute, EMBI, UK). The GenBank accession numbers for amino acid alignments were NP_001159435 for human SCN1A, NP_001033232 for human SCN2A, NP_0088533 for human SCN3A, NP_000925 for human SCN4A, NP_005906 for human SCN8A, NP_0002900 for human SCN9A, XP_001154150 for chimpanzee SCN1A, XP_001160920 for rhesus monkey SCN2A, NP_061203 for mouse SCN1A, NP_110502 for rat SCN1A, XP_001252710 for cattle SCN1A, XP_422021 for fowl SCN1A, and CAQ13572 for zebrafish SCN1A. Secondly, the mutations were analyzed by an online sequence homology-based tool, Sorting Intolerant from Tolerant (SIFT) (Genome Institute of Singapore, http://sift.bii.a-star.edu.sg/) [25]. Thirdly, a web-based program Align-GVGD (http://agvgd.iarc.fr/agvgd_input.php) [26], was used to predict whether the mutations are deleterious to protein functions by combining the biophysical properties of amino acids and multiple sequence alignment [27]. We applied the multiple sequence alignment used in our conservative analysis to Align-GVGD. Grantham Variation determined the range of toleration at a specific amino acid position and Grantham Deviation was the physicochemical difference between the wild type and mutated amino acid. The variants were classified into 7 groups (class 0, class 15, class 25, class 35, class 45, class 55 and class 65) in the program ranging from least likely (class 0) to most likely (class 65) to interfere the protein function. The two mutations in intron regions close to splice site were analyzed by another online software tools, Automated Splice Site Analyses (Laboratory of Human Molecular Genetics and Genomic Disorders, UWO, CA, https://splice.uwo.ca/) [28]. The functional domains in the amino acid sequence were defined by the database UniProt with accession number P35498.

Molecular Analysis of PCDH19 Gene

Mutations of PCDH19 genes were screened in the 3 SCN1A-negative DS patients and 13 female non-DS patients with clinical features resembling DS. The 6 exons of PCDH19 gene covering the coding regions as well as the splice junctions were amplified by PCR using oligonucleotide primers designed based on the sequence of PCDH19 gene on human chromosome X (GeneBank accession number: NG_021319). PCR, DNA sequencing, homology analysis and pathogenicity assessment were performed as mentioned above. GenBank accession numbers for amino acid alignments were Q5QTAB3 for human PCDH19; AA111561 for human PCDH10; CAA17092 for human PCDH17; AA43362 for human PCDH18; XP_003317603 for chimpanzee PCDH19; XP_001091349 for rhesus monkey PCDH19; Q80TF3 for mouse PCDH19; NP001162600 for rat PCDH19; DAA13144 for cattle PCDH19, and NP_001120991 for zebrafish PCDH19. The mutation nomenclature was based on the PCDH19 transcript reference sequence (GeneBank accession number: NM_020766) and nucleotides were numbered according to the cDNA with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence. The functional domains in the amino acid sequence were defined by the database UniProt with accession number Q5QTAB3.

Molecular Analysis of TSPYL1 and TSPYL4 Genes

Polymorphisms in both genes were extracted from the dbSNP database. Mutations of TSPYL1 gene were checked in the 3 SCN1A-negative DS patients and 25 non-DS patients with clinical features resembling DS. The coding sequence of TSPYL1 was amplified by PCR using primers designed based on the reference sequence of TSPYL1 gene on human chromosome 6 (GeneBank accession number: NC_000006). PCR, DNA sequencing, homology analysis and pathogenicity assessment were performed as mentioned above. GenBank accession numbers for amino acid alignments were NP_067680 for human TSPYL1, NP_005300 for human TSPYL1, XP_510704 for chimpanzee TSPYL1, NP_001118103 for rhesus monkey TSPYL1, NP_001094334 for cattle TSPYL4, NP_084479 for mouse TSPYL4, and NP_001012075 for rat TSPYL4. The mutation nomenclature was based on the reference sequence (GeneBank accession no.: NM_021648) and nucleotides were numbered according to the cDNA with +1 corresponding to the A of the ATG translation initiation codon.

Statistical Analysis

Chi-square test was employed to illustrate the relationship between types of SCN1A mutations (missense mutation versus truncating/splice site mutation) and the degree of ID of the patients (normal to mild ID versus moderate to severe ID). Statistical analysis was performed by statistical program PRISM V.5.0 (GraphPad Software Inc., San Diego, CA).

Results

Clinical Diagnoses (Table 1)

Eighteen patients (9 males, 9 females) were diagnosed to have DS. All DS patients had normal development before seizure onset and had onset before one year of age with an average onset age of 5.4 months. All patients experienced febrile seizures and had three or more types of seizures such as partial, generalized tonic-clonic, tonic, clonic, absence and myoclonic seizures. Prolonged seizures (>10 min) or status epilepticus were common and 16 DS patients had different grades of intellectual disabilities. Twelve patients (12/18; 66%) had autistic features compatible to the clinical diagnosis of Autism Spectrum Disorder. Eight patients (8/18; 44%) had a history of vaccination induced seizures. The remaining 82 patients were classified as non-DS patients as their clinical features could not fulfill the diagnostic criteria of DS.

SCN1A Mutations in Patients with Dravet Syndrome (Table 2)

Of the 18 DS patients examined, 15 (83%) were identified to have SCN1A mutations (Table 1). Six of these mutations were missense mutations, seven were non-sense or frameshift mutations, and two were mutations in intronic splice donor or acceptor sites (Table 2). These mutations spread throughout the whole SCN1A gene. Among the 6 missense mutations, 3 missense mutations (c.311C>T, p.A104V; c.1177C>T, p.R393C and c.4834G>A, p.V1612D) have been reported previously [8] and 3 missense SCN1A mutations were novel (c.1264G>A, p.V422M; c.2378C>T, p.T793M and c.3641T>G, p.I1214R). For the 7 truncating mutations, 2 (c.1348C>T, p.Q450X and c.569G>A, p.W190X) were reported previously [10,29] and 5 (c.1053T>A, p.S351X; c.2214G>A, p.W738X; c.2971-2972delGTGinsM, p.L991fsX992; c.4229delA, p.N1410fsX1411; c.4558delC, p.Q1520fsX1525) were novel. The two predicted aberrant splicings were resulted from 2 novel mutations in intron 3 (IVS3+3A>C) and intron 21 (IV21+1G>A). Most of the
Table 1. Summary of clinical characteristics of 18 patients with Dravet syndrome and 1 PCDH19-positive patient not grouped under Dravet syndrome.

| Case | Sex | Age (yr.) | Age of seizure onset (m.o.) | Febrile seizure | Seizure types | Prolonged seizures/status epilepticus | Intellectual disability | ASD | Vaccine induced | SCN1A mutation (other mutations) |
|------|-----|-----------|-----------------------------|-----------------|---------------|---------------------------------------|------------------------|-----|----------------|-------------------------------|
| 6    | F   | 15        | 6                           | +               | Partial       | + + + + + + + + + + + + + + + + + + | Moderate               | +   | −              | Truncation                    |
| 24   | F   | 18        | 10                          | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Moderate | +   | −              | Splice site                   |
| 40   | F   | 11        | 5                           | +               | Prolonged     | seizures/status epilepticus + + + + + + + + + + + + + + + + + + | Mild                   | +   | −              | Missense                      |
| 45   | M   | 9         | 7                           | +               | Febrile       | seizure + + + + + + + + + + + + + + + + + + | Normal (limited intelligence) | +   | −              | Splice site                   |
| 46   | M   | 10        | 4                           | +               | Partial       | + + + + + + + + + + + + + + + + + + | Mild                   | +   | DPT (onset)   | Missense                      |
| 53   | F   | 8         | 5                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Normal (learning problem)     | +   | Flu vaccine   | Truncation                    |
| 60   | F   | 5         | Day 3–4                      | +               | Febrile       | seizure + + + + + + + + + + + + + + + + + + | Severe                 | −   | −              | −                            |
| 65   | M   | 12        | 8                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Moderate | −   | DPT            | Missense                      |
| 71   | F   | 17        | 8                           | +               | Partial       | + + + + + + + + + + + + + + + + + + | Severe                 | +   | −              | Truncation                    |
| 74   | M   | 18        | 8                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Severe                 | +   | −              | Truncation                    |
| 75   | F   | 3         | 6                           | +               | Partial       | + + + + + + + + + + + + + + + + + + | Mild                   | −   | DPT            | Missense                      |
| 76   | M   | 3         | 3                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Mild                   | −   | 5 in 1 (onset) | Missense                      |
| 77   | M   | Died at 3 yr 4 | +               | +               | + + + + + + + + + + + + | Mild                   | −   | DPT (onset)   | Truncation                    |
| 85   | M   | 29        | 4                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Severe                 | +   | DPT            | Truncation                    |
| 89   | M   | 5         | 5                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Moderate | +   | DPaT           | Splice site                   |
| 94   | F   | 10        | 4                           | +               | Partial       | + + + + + + + + + + + + + + + + + + | Mild                   | +   | −              | Missense                      |
| 100  | M   | 8 mo. 3   | +                           | +               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | N.A.                  | −   | −              | Truncation                    |
| 83   | F   | 13        | 7                           | +               | Partial       | + + + + + + + + + + + + + + + + + + | Mild                   | −   | −              | − (Missense in PCDH19)       |
| 67 (non-DS) | F | 32        | 15                          | −               | Generalized   | tonic-clonic + Myo-clonic + Absences | + + + + + + + + + + + + | Mild                   | +   | −              | − (Missense in PCDH19)       |

Mild ID: general/developmental quotient = 50–70;
Moderate ID: general/developmental quotient = 25–50;
Severe ID: general/developmental quotient < 25;
DPT: diphtheria, pertussis and tetanus vaccination;
DPaT: DPT vaccines with acellular component of pertussis.

doi:10.1371/journal.pone.0041802.t001
mutations were in D1 and D2 of the SCN1A protein and no mutation were located in S4 voltage sensing segment. The types and locations of different mutations found in the 15 DS patients were summarized in Table 2 and Fig. 1. No SCN1A mutation was detected in the coding region of SCN1A in the other 5 DS patient. Parental DNAs of 14 mutation positive cases were available for SCN1A gene analysis and 1 out of 15 cases were unavailable. Analysis of parental DNA confirmed that 12 cases of mutations were de novo, 2 mutations (p.V1612I and p.T793M) were inherited maternally. As the mothers of these 2 patients had the same mutation but remain asymptomatic, the inherited mutations do not fully explain the phenotypes. None of the mutations were found in 100 normal control alleles. Among the 15 DS patients with SCN1A mutations, 8 patients (53%) had a history of seizures following vaccinations. Three of these patients had onset of first seizures related to vaccination. The majority (75%) of seizures occurred after DPT vaccinations. There was no history of vaccination-induced seizure for the 3 DS patients with no mutation.

Parental DNAs of 14 mutation positive cases were available for gene analysis and 1 out of 15 cases were unavailable. None of the mutations were found in 100 normal control alleles.

**PCDH19 Mutations**

One of the SCN1A-negative female DS patients (case 83) was identified to have a novel PCDH19 missense mutation in exon 1 (c.1129G>A, p.D377N) (Table 1, 2). One non-DS female patient (case 67) was identified to have another exon 1 missense mutation (c.1019A>G, p.N340S). She presented with severe phenotype of epilepsy and ID overlapping with the features of DS but the onset of seizures was 15 months. Both missense mutations caused amino acid change in the extracellular domain of PCDH19 with p.D377N in extracellular cadherin-4 (EC4) domain and p.N340S in EC3 domain (Fig.1). Parental DNA of case 83 was screened and the mutation was confirmed to be de novo. Parental DNA of the other case was unavailable. None of the mutations were found in 100 normal control alleles.

**TSPYL1 Polymorphisms (Table 3)**

From NCBI dbSNP, 30 SNPs were reported in the 1314 bp coding region of TSPYL1 gene. Among these 30 SNPs, 10 SNPs were missense, 6 were synonymous, 3 were insertions and 3 were frameshifts. The nucleotide changes of the 6 insertions/frameshifts were shown in Table 3. Out of these insertions/frameshifts, 4 resulted in premature stop (rs56100890, rs80099151, rs144304201, rs14664109) and the rest resulted in insertion/deletion of amino acids. The 4 SNPs leading to premature stop were expected to result in loss-of-function. As deleterious variations in TSPYL1 were identified in the general population, mutation screening in our patients was not performed.

**TSPYL4 Variant**

The DS patients (case 83) with the de novo D377N PCDH19 mutation was found to have a missense variant in TSPYL4 gene (c.178G>C, p.G60R) (Fig.1, Table 1, 2). This variant was maternally inherited and the patient’s mother was asymptomatic. The variant was not found in 100 normal control alleles.

**Analyses of Missense and Splice Site Mutations (Table 4)**

The conservation analysis (Fig. 2) in the present study revealed that the 6 missense SCN1A mutations, 2 PCDH19 mutations and 1 TSPYL4 variant affected highly conserved amino acids. In addition, SIFT analyses predicted that these 9 missense mutations affected protein function. By Align-GVGD analysis (Table 4), the 9 missense mutations were assigned a high class and given an increase likelihood to be deleterious in different extents (p.V1214R, p.A104V, p.R393C and p.G60R).

---

**Table 2. Summary of SCN1A, PCDH19 and TSPYL4 mutations found in 17 patients.**

| Gene   | Case | Dravet syndrome (+/-) | Type of mutation | Amino acid | Exon | Nucleotide | Location in protein | De novo |
|--------|------|-----------------------|------------------|------------|------|------------|---------------------|---------|
| SCN1A  | 6    | Frameshift            | p.L991fsX992     | 16         | c.2971–2972delCTinsG | S6 of D2            | +       |
|        | 77   | Frameshift            | p.N1410fsX1411   | 21         | c.4229delA       | SS–S6 of D3         | +       |
|        | 100  | Frameshift            | p.Q1520fsX1538   | 24         | c.4558delC       | D3–D4 loop          | +       |
|        | 53   | Nonsense              | p.Q450X          | 9          | c.1348C>T       | D1–D2 loop          | +       |
|        | 71   | Nonsense              | p.W190X          | 4          | c.569G>AG       | S3 of D1            | +       |
|        | 74   | Nonsense              | p.W738X          | 13         | c.2214G>A       | D1–D2 loop          | +       |
|        | 85   | Nonsense              | p.C351X          | 8          | c.1053T>A       | SS–S6 of D3         | +       |
|        | 24   | Splice site           | –                 | Intron 21  | IVS21+1G>A     | SS–S6 in D3         | +       |
|        | 89   | Splice site           | –                 | Intron 3   | IVS3+3A>C      | S2 of D1            | +       |
|        | 40   | Missense              | p.T793M          | 13         | c.2378C>T      | S1–S2 of D2         | Maternal |
|        | 46   | Missense              | p.A104V          | 2          | c.311C>T       | N-terminus          | +       |
|        | 65   | Missense              | p.V1612I         | 25         | c.4834G>A      | S3 of D4            | Maternal |
|        | 75   | Missense              | p.R393C          | 9          | c.1177C>T      | SS–S6 of D1         | +       |
|        | 76   | Missense              | p.V422M          | 9          | c.1264G>A      | S6 of D1            | +       |
|        | 94   | Missense              | p.I1214R         | 18         | c.3641T>G      | S1 of D3            | +       |
| PCDH19 | 67   | –                     | p.N340S          | 1          | c.1019A>G      | EC3                 | N.A.    |
|        | 83   | –                     | p.D377N          | 1          | c.1129G>A      | EC4                 | +       |
| TSPYL4 | 83   | –                     | p.G60R           | –          | c.178G>C      | N- to NAP           | Maternal |

D1–D4: four homologous domains of SCN1A; S1–S6: six transmembrane segments in the four domains of SCN1A; EC: extracellular domain of PCDH19; NAP: domain of nucleosome assembly protein of TSPYL4.

doi:10.1371/journal.pone.0041802.t002
were classified as C65; p.N340S was classified as C45; p.V1612I was classified as C25; p.T793M, p.V422M and p.D377N were classified as C15). Automated Splice Site Analyses revealed that both intronic mutations in SCN1A could abolish the splice donor sites and caused aberrant splicing.

SCN1A Variations in Patients not Grouped under Dravet Syndrome

No SCN1A mutations were found in the 82 non-DS patients. Two variations resulting in amino acid substitutions (p.A464P and p.D516N) were found in 2 out of 82 non-DS patients. Pathogenicity assessment predicted that these two substitutions were tolerated and less likely to interfere protein functions (Table 4).

Table 3. Six insertion/frameshift SNPs of TSPYL1 from NCBI dbSNPs.

| SNP         | Nucleotide change                          |
|-------------|--------------------------------------------|
| rs67074252  | c.520_521insGGT                           |
| rs56100880  | c.521_522insGGT                           |
| rs80099151  | c.522delG; c.522delGinsGGT                |
| rs144384201 | c.523_524delGT; c.523_524delGTinsGGT      |
| rs140644109 | c.527_528delTG; c.527_528delTGGinsGGT     |
| rs78371471  | c.528_529insGTG                           |

Intellectual Disability and SCN1A Mutation

Seven patients had truncating mutation in SCN1A gene, of which 3 (cases 71, 74 and 85) had severe ID, 1 (case 6) had moderate ID, 1 (case 77) had mild ID and 1 (case 53) was normal. The 2 patients (cases 24 and 89) with splice site mutation had moderate ID. On the other hand, 5 patients (cases 40, 46, 75, 76 and 94) with missense mutations had only mild ID and 1 of them (case 65) had moderate ID. Chi-square test showed that there was a relationship between types of SCN1A mutation (missense mutation versus truncating/splice site mutation) and the degree of ID (normal to mild ID versus moderate to severe ID) (p<0.05).

This indicated that the patients with missense mutations tend to have less severe ID than those with either truncating or splice site mutations (Fig. 3). The 8-month-old DS patient with truncating mutation (case 100) was not included in this analysis as he was too young and long term cognitive outcome was still undetermined.

Discussion

SCN1A Mutations in 15 Patients with Dravet Syndrome

In this study, we have found 9 truncating and splice site mutations among the 15 SCN1A mutations in DS patients. Most truncating mutations terminated the protein at first 2 domains. Early truncating mutations are mostly associated with severe epileptic phenotypes in DS, although in a previous study, they caused only milder epilepsy with GEFS+ and focal seizures in 2 patients [30]. In the present study, all truncating and splice site mutations were de novo and linked to DS with severe ID.

In contrast to the truncating and splice site mutations, the association of missense mutations with phenotypic expression of DS patients is more controversial. In this study, we used conservative analysis, SIFT analysis and Align-GVGD to assess the interference of the amino acid substitutions to the protein...
functions. p.V1612I has been reported in the study of Depienne et al [10] and Herini et al [31] associated with DS. p.R393C has been reported previously in several studies [5,10,29,32] and this mutation was all found in SMEI patients except in the study of Harkin et al [5] who identified the R393C mutation in a patient with myoclonic astatic epilepsy. According to the analysis in Depienne et al. [10] study, both p.R393C and p.V1612I mutations alter highly conserved amino acid residues in the protein. p.R393C substitution involves a very dissimilar change in amino acid residue but p.V1612I substitution only has a slight influence chemically according to Grantham distance determination. However, V1612I substitution alters amino acid in a highly conserved ion transport sequence [10]. In the present study, Align-GVGD analysis showed that p.V1612I substitution can possibly affect protein function (Align-GVGD classified to C25). No mutational analysis of p.A104V has been published previously. We illustrated here that this mutation affects a highly conserved amino acid which is substituted with a chemically dissimilar residues (GD = 65.28) in the N-terminus and very likely (Class C65) to affect SCN1A protein function. Conservative analyses has showed that the three novel mutations (p.V422M, p.T793M and p.L1214R) change highly conserved amino acid residues in the protein and pathogenicity assessment indicated these mutations produce dissimilar changes in amino acids. They change protein function in different extents and are associated with severe phenotypes of the 3 DS patients. By contrast, the 2 substitutions (p.A104V and p.D516N) involve less conserved amino acid residues are predicted to be tolerated and less likely to affect protein function. The two patients with these substitutions were diagnosed as non-DS. These findings illustrated the significance of pathogenicity assessments in elucidating the association of amino acid substitutions with the clinical expression of the DS patients.

Nevertheless, the association between the clinical phenotypes and SCN1A mutations is still poorly understood. First, it is unclear how missense mutations can cause an epileptic phenotype similar to truncating mutations. A possible mechanism is haploinsufficiency [10]. Heterozygosity of both loss-of-function truncating and deleterious missense mutations can result in quantitative reduction in normal functioning sodium channel which causes severe phenotypes in DS [10,33]. Second, both inherited missense mutations (p.V1612I and p.T793M) in the present study were inherited from asymptomatic mothers. In the other reported cases of inherited SCN1A mutations [8] including truncating mutations [34], the transmitting parents were also asymptomatic or of mild epileptic phenotypes. Somatic mosaicism of the parents have been shown to account for this phenomenon [35,36,37]. It is also possible that SCN1A mutation is not the only factor for the phenotypes in DS patients and other genetic background and environmental factors are involved to produce synergistic effect to the disease. In response to this issue, Depienne et al [11,35] proposed the possibility of a variable expression of mutation in the brain of asymptomatic parents. They suggested that peripheral mosaicism like blood cells does not always reflect the neuronal mosaicism although they showed that the clinical status of mosaic parents correlated with the percentage (0–85%) of mutation in their blood cells. Meisler and Kearney [33] also proposed several factors such as developmental variability, accumulation of somatic mutation in lifetime, environmental insults and modifier genes which may exacerbate the phenotypes of individuals carrying SCN1A mutations. Further investigations on other interacting genetic, developmental and environmental elements will bring more insight into these issues.

Interestingly, here we found no mutation in S4, the voltage sensor region as defined by Kanai et al [38], in contrast to the finding in Zuberi et al [12] that the missense mutations occurred with a higher frequency in S4 region. Besides, there was no preferential localization of mutations in S3–S6 segment, the pore forming region, which was reported previously to have higher frequency of missense mutations in SMEI patients [12,38]. In agreement with our study, Depienne et al [10] also failed to demonstrate any preferential localization in S5–S6 segment. So, the present study did not support a relationship between the

Table 4. Pathogenicity assessment of 9 missense mutations and 2 tolerated amino acid substitutions.

| Gene   | Change of amino acid in missense mutation | Location in protein | Conservative analysis† | SIFT analysis | Align-GVGD analysis |
|--------|------------------------------------------|---------------------|------------------------|--------------|---------------------|
| SCN1A  | p.T793M                                  | S1–S2 of D2         | +                      | +            | 85.08               |
|        | p.A104V                                  | N-terminal          | +                      | +            | 0.00                |
|        | p.V1612I                                 | S3 of D4            | +                      | +            | 0.00                |
|        | p.R393C                                  | S5–S6 of D1         | +                      | +            | 0.00                |
|        | p.V422M                                  | S6 of D1            | +                      | +            | 0.00                |
|        | p.I1214R                                 | S1 of D3            | +                      | +            | 0.00                |
| PCDH19 | p.N340S                                  | EC3                 | +                      | +            | 0.00                |
|        | p.D377N                                  | EC4                 | +                      | +            | 0.00                |
| TSPYL4 | p.G60R                                   | N- to NAP           | +                      | +            | 0.00                |
| SCN1A  | p.D516N                                  | D1–D2 loop          | –                      | –            | 353.86              |
|        | p.A464P                                  | D1–D2 loop          | –                      | –            | 110.77              |

†For conservative analysis, “+” indicates the amino acid residue is highly conserved and “−” indicates it is less conserved.
‡For SIFT analysis, “+” indicates the variant affect protein function and “−” indicates that it is tolerated.
§The variants were classified into 7 groups (class 0, class 15, class 25, class 35, class 45, class 55 and class 65) ranging from least likely (class 0) to most likely (class 65) to interfere the protein function (http://agvgd.iarc.fr/classifiers.php).

D1–D4: four homologous domains of SCN1A; S1–S6: six transmembrane segments in the four domains of SCN1A; EC: extracellular cadherin domain of PCDH19; SMEI: severe myoclonic epilepsy in infancy.

Mutations in Dravet Syndrome
Figure 2. Evolutionary conservations of amino acid substitutions found in SCN1A, PCDH19 and TSPYL4.
doi:10.1371/journal.pone.0041802.g002
localization of mutation and the severity of the diseases and all SCN1A mutations are severe in DS patients.

Association of SCN1A Mutation with Intellectual Disability and Autism Spectrum Disorder

In DS patients, developmental regression in the second year, cognitive deficits as well as behavioral disturbances are common [3]. In the present study, patients with missense mutations tend to be associated with less severe ID than those with either truncating or splice site mutation. These data suggested a possible correlation between the type of SCN1A mutation and mental development of DS patients. Riva et al [39] also proposed that SCN1A mutation, rather than epilepsy, was responsible for the progressive cognitive impairment. They showed that two DS children carrying SCN1A truncating mutations had their cognitive performance continued to deteriorate irrespective of the difference in their epilepsy severities. However, the study of Ragona et al [40] failed to demonstrate a significant difference in the cognitive outcome of 26 cases with regard to the presence and type of SCN1A mutation. They showed that the worst cognitive outcome was associated with early appearance of myoclonus and absences. A recent review also suggested that modifier genes present in DS patients may be the factor affecting the cognitive outcome [41]. Additional clinical investigations with large sample sizes will be necessary to elucidate the correlation between cognitive development in DS patients and the types of SCN1A mutations.

In the present study, 11 (73%) out of 15 DS patients with SCN1A mutation had ASD in the present study. A previous study identified four missense mutation in SCN1A gene, one coding mutation in SCN2A gene from different autism families [42] and suggested that mutations in the sodium channel genes may play a role in autism susceptibility. O’Roak et al [43] also found a functionally deleterious SCN1A missense mutation in a patient with sporadic ASD. These findings indicate that autism may be one of the possible consequences of SCN1A mutation. Osaka et al [44] identified a novel SCN1A mutations in two patients with both seizures and psychiatric disorders including panic disorder and Asperger syndrome. They suggested that SCN1A mutation may contribute to the expression of psychiatric disorders in addition to epileptic seizures and combined effect of different gene variants may determine the ultimate phenotype of patients [33,42]. Li et al [45] reported that the DS patients with autism had more severe ID [45]. However, in the present study, DS patients with ASD could have mild, moderate or severe grade of ID and there is no association with the degree of ID. Association of SCN1A mutation in epilepsy patients with evolving autistic features is an interesting topic for future clinical research.

Vaccination-induced Seizures or Vaccine Induced Encephalopathy in Patients of Dravet Syndrome with SCN1A Mutations

In the present study, 8 DS patients with SCN1A mutations had a history of seizures following vaccinations. Our finding elucidated that seizures after vaccinations are common in DS patients (8/18; 44%) and it is also the case in the study of Tro-Baumann et al [46] with 19 (27%) of 70 patients having seizures after vaccination. In contrast, the rate of febrile seizures occurring in general population is much lower (6–9 and 25–34 per 100,000 children) after DPT and MMR vaccines administration [47]. The high rate of vaccination-induced seizures in DS patients with SCN1A mutation (53%) may be connected to the genetically determined aberrant functioning of sodium channels. Berkovic et al [47] have also suggested that vaccination is unlikely to be the significant trigger of the encephalopathy in DS patients with SCN1A mutation and avoiding vaccination will not prevent the onset of disorders. Further genetic study on patients with vaccination-induced seizures should be considered. Testing for SCN1A mutations will be necessary for those infants suspected to have DS in order to provide early management in terms of temperature and infection controls.

PCDH19 Mutations in 2 Patients

PCDH19 is another susceptibility gene for female patients of DS. In the present study, one of the two SCN1A-negative female DS patients was identified to have a novel PCDH19 mutation (p.D377N). Pathogenicity assessment showed that this mutation changes highly conserved amino acids in EC4 domain and affects protein function. This PCDH19-positive DS patient shared the same clinical features with other DS patients except the absence of both myoclonic and absence seizures. Besides, this patient had clusters of seizures during febrile episodes which was another distinguishing feature observed in PCDH19-positive patients as suggested by Depienne et al [48]. The proportion of PCDH19 mutation among DS patients (5.6%) in the present study was comparable to Depienne et al [22] study. Depienne et al [22] suggested that PCDH19 might contribute significantly to epileptic encephalopathies with clinical spectrum overlapping that of DS. They showed that PCDH19-DS and SCN1A-DS had many common features including early onset of seizures, association of generalized tonic-clonic and focal seizures, prolonged seizures and developmental regression. But they differed slightly as PCDH19-DS might have a later seizure onset, less intractable seizure, absence of status epilepticus, myoclonic jerks/atypical absences and less severe intellectual/language delay.

Another PCDH19 mutation (p.N340S) was found in a non-DS patient. Both patients with a PCDH19 mutation shared similar clinical features including the presence of both partial and generalized seizure types, occurrence of status epilepticus and mental retardation. However, the non-DS patients had seizure onset after 1 year (15 months). p.N340S has been reported previously in three studies [22,49,50]. In the studies of Depienne et al [22] and Marini et al [49], the patients with p.N340S mutations were diagnosed as DS. However, the sister pair with this
mutation in the study of Dibben et al. [50] were diagnosed as EFM. They had seizure onset at 13 and 17 months, refractory seizure and developmental slowing. Patients with PCDH19 mutations in other studies [15,16,48] were also shown to be non-DS with seizure onsets after 1 year. Taken together, in addition to DS patients, PCDH19 mutation screening should also be considered for patients with clinical features resembling DS with seizure onset after 1 year old.

**TSPYL4 Variant in 1 Patient**

Interestingly, a new TSPYL4 variant was found in a DS patient with a novel *PCDH19* p.D377N mutation. The amino acid substitution p.G66R occurs in a highly conserved amino acid and is likely to interfere with protein function according to pathogenicity assessment. Nevertheless, it is N-terminal to the conserved nucleosome assembly protein domain. In addition, the DS patient with the TSPYL4 mutation is also PCDH19-positive and his mother carrying the TSPYL4 mutation is asymptomatic. Besides, the role of TSPYL4 in epilepsy has not been reported previously. Taken together, the TSPYL4 variant we identified is unlikely to be pathogenic.

**Author Contributions**

Conceived and designed the experiments: VCNW AKYK CWF. Performed the experiments: AKYK VCNW CWF. Analyzed the data: AKYK SYC. Contributed reagents/materials/analysis tools: VCNW AKYK. Wrote the paper: AKYK CWF VCNW SYC.

---

**References**

1. Audenaert D, Van Broeckhoven C, De Jonghe P (2006) Genes and loci involved in febrile seizures and related epilepsy syndromes. Hum Mutat 27: 391–401.
2. Singh R, Andermatten E, Whitehouse WP, Harvey AS, Keene DL, et al. (2003) Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? Epilepsia 42: 837–844.
3. Dravet C (2011) The core Dravet syndrome phenotype. Epilepsia 52 Suppl 2: 3–9.
4. Dravet C, Bureau M, Ogumi H, Fukunaya Y, Cokar O (2005) Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Hofer J, Dravet C, Genton P, Tassinari C, Wolf P, editor: Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libby: 89–113.
5. Harkin LA, McMahon JM, Iona X, Dibbens L, Polkanos JT, et al. (2007) The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130: 843–852.
6. Martina M, Vida I, Jonas P (2000) Distal initiation and active propagation of action potentials in interneuron dendrites. Science 287: 295–300.
7. Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, et al. (2000) Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+. Nat Genet 24: 345–345.
8. Claes LR, Delaloye SJ, Suls A, Baris J, Snets K, et al. (2009) The SCN1A variant database: a novel research and diagnostic tool. Hum Mutat 30: E904–920.
9. Yamakawa K (2006) Na channel gene mutations in epilepsy—the functional consequences. Epilepsy Res 70 Suppl 1: S120–222.
10. Depienne C, Trouillard O, Saint-Martin C, Gourfinkel-An I, Bouteiller D, et al. (2006) Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 43: 186–193.
11. Depienne C, Trouillard O, Gourfinkel-An I, Saint-Martin C, Bouteiller D, et al. (2010) Mechanisms for variable expression of inherited SCN1A mutations causing Dravet syndrome. J Med Genet 47: 404–410.
12. Zuberi SM, Blankkauk A, Birch R, Reavey E, Dunbag J, et al. (2011) Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 76: 594–600.
13. Mantanagelo M, Leuzzi V (2012) Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol 46: 246–311.
14. Dibbens LM, Tarpey PS, Hynes K, Baulay MA, Schefler EE, et al. (2008) X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 40: 776–781.
15. Hynes K, Tarpey P, Dibbens LM, Baulay MA, Berkovic SF, et al. (2010) Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in several generation families. J Med Genet 47: 211–216.
16. Jamal SM, Basran RK, Newton S, Wang Z, Mihajlyk JM (2010) Novel de novo PCDH19 mutations in three unrelated females with epilepsy female restricted mental retardation syndrome. Am J Med Genet A 152A: 2475–2481.
17. Wu Q, Maniatis T (1999) A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell 97: 779–790.
18. Yagi T, Takeichi M (2000) Cadherin superfAMILY genes: functions, genomic organization, and neurologic diversity. Genes Dev 14: 1169–1180.
19. Vanhalst K, Kools P, Staes K, van Roy F, Redies C (2005) delta-Protocadherin—a gene family expressed differentially in the mouse brain. Cellular and molecular life sciences : CMLS 62: 1247–1259.
20. Kim SY, Chung HS, Sun W, Kim H (2007) Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain. Neuroscience 147: 996–1021.
21. Scheffer IE, Turner SJ, Dibbens LM, Baulay MA, Friend K, et al. (2008) Epilepsy and mental retardation limited to females: an under-recognized disorder. Brain. 131: 916–927.
22. Depienne C, Bouteiller D, Keren B, Cheuret E, Poirier K, et al. (2009) Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet 5: e1000381.
23. Podar A, Wang Y, Gordon D, Barral-Rodriguez S, Barker-Cummings C, et al. (2009) Novel susceptibility locus at chromosome 6q16.3-22.31 in a family with GEFS+. Neurology 73: 1264–1272.
45. Li BM, Liu XR, Yi YH, Deng YH, Su T, et al. (2011) Autism in Dravet syndrome: Prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav 21: 291–295.
46. Tro-Raumann B, von Spiczak S, Lotte J, Baut T, Haberlandt E, et al. (2011) A retrospective study of the relation between vaccination and occurrence of seizures in Dravet syndrome. Epilepsia 52: 175–178.
47. Berkovic SF, Harkin L, McMahon JM, Pelekanos JT, Zuberi SM, et al. (2006) De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 5: 488–492.
48. Depienne C, Trouillard O, Bouteiller D, Gourfinkel-An I, Poirier K, et al. (2011) Mutations and deletions in PCDH19 account for various familial or isolated epilepsies in females. Hum Mutat 32: E1959–1975.
49. Marini C, Mei D, Parmeggiani L, Norci V, Calado E, et al. (2010) Protocadherin 19 mutations in girls with infantile-onset epilepsy. Neurology 75: 646–653.
50. Dibbens LM, Kneen R, Bayly MA, Heron SE, Arsov T, et al. (2011) Recurrence risk of epilepsy and mental retardation in females due to parental mosaicism of PCDH19 mutations. Neurology 76: 1514–1519.